Clinical Scorecard: Geographic Atrophy: Early Detection and Patient Awareness Matters
At a Glance
| Category | Detail |
|---|---|
| Condition | Geographic Atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) |
| Key Mechanisms | Accumulation of drusen, loss of photoreceptor cells, retinal pigment epithelium (RPE) changes, and retinal and choroidal atrophy leading to atrophic macular lesions |
| Target Population | Patients at risk for or living with Geographic Atrophy, including over 1 million people in the US and about 8 million worldwide |
| Care Setting | Optometry and ophthalmology clinics with access to advanced diagnostic imaging and intravitreal complement inhibition pharmacotherapy |
Key Highlights
- GA is irreversible and progresses faster than previously thought, accounting for approximately 20% of legal blindness.
- From initial diagnosis, significant vision impairment typically occurs within 2 years as atrophic lesions invade the fovea.
- Early detection, close monitoring, and timely referral for complement inhibitor treatment are critical to slow progression and preserve vision.
Guideline-Based Recommendations
Diagnosis
- Use multimodal imaging including color fundus photography (CFP), fundus autofluorescence (FAF), and optical coherence tomography (OCT) to identify GA lesions and RPE atrophy.
- Monitor OCT biomarkers such as drusenoid pigment epithelial detachment (PED) softening, RPE disruption, incomplete RPE and outer retinal atrophy (iRORA), and progression to complete RPE and outer retinal atrophy (cRORA).
Management
- Refer patients promptly for intravitreal complement inhibition pharmacotherapy upon diagnosis or progression of GA.
- Prioritize patient education to increase awareness and adherence to monitoring and treatment plans.
Monitoring & Follow-up
- Conduct regular follow-up imaging to assess progression of GA lesions and retinal atrophy.
- Track visual acuity changes and structural OCT biomarkers to guide timely intervention.
Risks
- GA progression leads to irreversible vision loss and legal blindness.
- Delayed diagnosis and referral may result in faster vision impairment as lesions invade the fovea.
Patient & Prescribing Data
Patients diagnosed with Geographic Atrophy, particularly those with extrafoveal lesions progressing toward the fovea
Intravitreal complement inhibition pharmacotherapy is the current intervention to slow GA progression; early referral and treatment initiation improve outcomes.
Clinical Best Practices
- Educate patients on the importance of early detection and adherence to follow-up visits.
- Leverage advanced multimodal imaging techniques for accurate diagnosis and monitoring.
- Ensure timely referral to retinal specialists for pharmacologic intervention.
- Maintain close monitoring of OCT biomarkers indicative of GA progression.
- Support patients with counseling to preserve quality of life despite progressive vision loss.
References
- Prevalence and impact of Geographic Atrophy
- GA progression and vision impairment timeline
- Multimodal imaging in GA diagnosis and monitoring
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.